You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,974,760

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,974,760

Title:	Compositions and methods for treating cancer
Abstract:	The present invention provides, in part, compositions and methods for treating cancer using a combination of C6-ceramide and other anti-cancer agents.
Inventor(s):	Wanebo; Harold J. (Bristol, RI)
Assignee:	Chemo-Enhanced LLC (Woonsocket, RI)
Application Number:	15/352,166
Patent Claims:	1. A method for treating pancreatic cancer having an activating KRAS mutation, wherein the activating KRAS mutation is a human KRAS polypeptide having a mutation selected from the group consisting of G12C, G12A, G12D, G12R, G12S, G12V, G13C, and G13D, comprising administering to a human a pharmaceutically acceptable formulation comprising (a) an effective amount of C6-ceramide; and (b) an effective amount of at least one anti-cancer agent selected from 5-fluorouracil, cetuximab and gemcitabine. 2. The method of claim 1, wherein administering the pharmaceutically acceptable formulation is effected by parenteral or oral administration. 3. The method of claim 1, wherein the cancer is affected synergistically with respect to administering (a) and (b) relative to administering either (a) or (b) alone. 4. The method of claim 1, wherein the anti-cancer agent comprises 5-fluorouracil. 5. The method of claim 1, wherein the anti-cancer agent comprises cetuximab. 6. The method of claim 1, wherein the anti-cancer agent comprises gemcitabine. 7. The method of claim 1, wherein the anti-cancer agent is 5-fluorouracil. 8. The method of claim 1, wherein the anti-cancer agent is cetuximab. 9. The method of claim 1, wherein the anti-cancer agent is gemcitabine. 10. The method of claim 2, wherein administering the pharmaceutically acceptable formulation is effected by parenteral administration; and parenteral administration is selected from intravenous, intraperitoneal, intralymphatic, intralesional, and subcutaneous.

Details for Patent 9,974,760

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004	⤷ Try a Trial	2031-04-06
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007	⤷ Try a Trial	2031-04-06
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.